Every 424B that Enlivex Ltd. (ENLV) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow ENLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ENLV filings page.
Enlivex Ltd. is registering for resale up to 10,000,000 ordinary shares that may be sold from time to time by the holder of its Senior Secured Convertible Promissory Note, without Enlivex receiving any proceeds from these sales. The shares are issuable under a $21.0 million note issued in a March 23, 2026 private placement for an aggregate purchase price of $19.0 million. The note matures on March 23, 2027, is senior secured, does not bear interest unless in default when a 10.0% annual rate applies, and is repayable in nine monthly principal installments of approximately $2.3 million, in cash, shares, or a combination. The note is convertible at an initial price of $40.37625 per share and may be prepaid at 105% of outstanding principal or, upon certain events of default, be put back to Enlivex at 110% of outstanding principal. Enlivex’s ordinary shares trade on the Nasdaq Capital Market under the symbol ENLV, with 17,485,462 shares outstanding as of August 5, 2026, and a last reported price of $1.84 per share on August 12, 2026.
Enlivex Ltd. registers 23,333,333 ordinary shares for resale by a selling shareholder pursuant to a senior secured convertible promissory note. The shares are issuable under the Note and represent the company’s good-faith estimate of the maximum Note Conversion Shares. The company will receive no proceeds from resales; net proceeds go to the selling shareholder.
ENLV is updating an at-the-market offering: it is now offering up to $250,000,000 of ordinary shares for sale pursuant to an At-The-Market Sales Agreement with BTIG, LLC.
The supplement notes the company initially registered up to $299,553,108 under the agreement and that, from November 24, 2025 through the supplement date, the company sold an aggregate of 1,936,660 ordinary shares for aggregate gross proceeds of $2,513,111. Sales may be made from time to time in at-the-market transactions under the Sales Agreement; the offering amount here excludes shares previously sold under the Prospectus.
Enlivex Therapeutics Ltd. has launched an at-the-market equity program to sell up to $299,553,108 of ordinary shares through BTIG on Nasdaq or other U.S. markets. Net proceeds are intended mainly for acquiring RAIN governance tokens and building a new digital asset treasury business, alongside working capital and ongoing clinical, regulatory, manufacturing and R&D activities.
The company plans to concentrate its treasury in RAIN and use staking and DeFi strategies while relying on third-party custodians, exposing it to significant crypto price, liquidity, regulatory and cybersecurity risks. Enlivex continues its macrophage reprogramming program, reporting positive Phase IIa six‑month data in knee osteoarthritis patients aged 60+ with clinically meaningful pain and function improvements versus placebo. Recent actions also include a large private placement of 212,000,000 shares or pre-funded warrants at about $1.00 and an option to purchase up to $918.0 million of RAIN tokens.